
Biological evolution of molecular markers in breast cancer
Clinical implications of biomarker changes
Proliferative markers: prognostic and predictive role
Biopsy of metastases in breast cancer patients
Positive sentinel node: can we avoid axillary dissection?
- YES we can
- NO, except when...
Partial breast cancer irradiation:
- When could be done
- When should not be done
Early Breast Cancer: systemic treatment. An update
Intensive follow up after primary curative therapy
Primary systemic therapy: biological and clinical end points
Breast reconstruction and radiation therapy
Management after primary systemic therapy
Preservation of fertility and pregnancy after breast cancer
Male breast cancer
Management of advanced breast cancer patients: how to translate scientific advances into daily practice
Management of elderly breast cancer patient
New bone targeting agents
Clinical and ethical challenges in treatment decision
Challenges in drug development and accessibility. a view from different perspectives: scientists, clinicians, pharma representatives, regulatory officials, payers, patients, media representatives.
Clinical genomics for personalized cancer medicine
Immunotherapy for breast cancer: premises and promises
- HR + disease
- HER2+ disease
- Triple negative

University Hospital of Modena
University of Modena-Reggio Emilia (I)
Scientific Director
Istituto Oncologico Veneto
Padova (I)
Department of Surgery, Oncology and Gastroenterology
University of Padova (I)
Integrated Department of Oncology, Hematology and Respiratory Diseases
University Hospital of Modena
University of Modena and Reggio Emilia (I)
Oncology Research and Treatment Center
Ankara University (T)
Department of Oncology and Radiotherapy Medical
University of Gdansk (PL)
NIHR Biomedical Research Centre for Cancer
Royal Marsden NHS Foundation Trust & Institute of Cancer Research
London (UK)
Reggio Emilia (I)
Padova (I)
Milano (I)
Stockholm (SW)
Summit – NJ (USA)
Padova (I)
Modena (I)
Roma (I)
Genova (I)
Houston (USA)
Modena (I)
Houston, TX (USA)
Ankara (TR)
Gdansk (PL)

University of Texas - MD Anderson Cancer Center
Houston (USA)
Medical Oncology Department
Salpetriere Hospital
Paris (F)
German Breast Group
University
Frankfurt (D)
Medical Oncology Service
Hospital Universitario Gregorio Maranon
Madrid (S)
Department of Surgery, Oncology and Gastroenterology
University of Padova (I)
Department of Radiation Oncology
Dr. Verbeeten Instituut
Tilburg (NL)
Clinical Division of Oncology Medical
University - General Hospital
Vienna (A)
London (UK)
Paris (F)
Frankfurt (D)
Madrid (S)
Milan (I)
Collegeville PA (USA)
Tilburg (NL)
Genova (I)
Houston (USA)
Milan (I)
Padova (I)
Padova (I)
Vienna (A)
The registration fee is € 250,00 tax free. It includes the conference bag, the conference book and all coffee breaks and lunches. It does not include hotel accomodation, dinners and travel expenses.
To register, please send:
to: Accademia Nazionale di Medicina, Palazzina CUP ii Piano, via Massarenti 9, 40138 Bologna (fax 0039.051.636.46.05 – email: info.bologna@accmed.org), within November, 2nd 2012.
By submitting the form and the payment, your registration is completed with the exception of specific decisions of the Meeting secretariat. Incomplete registration will NOT be admitted. The registration will be confirmed by e-mail
If the participants minimum number is not reached, Accademia Nazionale di Medicina will advise by a written communication and proceed with the total refund of the fee.
In order to cancel please give advise with a written communication to Accademia Nazionale di Medicina within 10 days from the beginning. A 70% of the registration fee will be returned. Any cancellation after that deadline will not be reimbursed.